Similar articles

• Application of target-specific drug immunoconjugates to experimental bone marrow replacement therapy in mice.

  Ding L, Yu LZ, Xie SS, Gong D, Vergidis R, Diener E. Ding L, et al. Cancer Res. 1990 Mar 1;50(5):1538-43. Cancer Res. 1990. PMID: 2302715
• The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.

  Stastny JJ, Das Gupta TK. Stastny JJ, et al. Cancer Res. 1993 Dec 1;53(23):5740-4. Cancer Res. 1993. PMID: 8242630
• Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.

  Tonevitsky AG, Agapov II, Mechetner EB, Ershova GV, Toptygin AYu, Sarma T, Shamshiev AT, Pfueller U. Tonevitsky AG, et al. Biochem Mol Biol Int. 1993 Dec;31(6):1059-69. Biochem Mol Biol Int. 1993. PMID: 8193589
• The use of anthracycline-antibody complexes for specific antitumor activity.

  Pietersz GA, Smyth MJ, Farquhar I, McKenzie C. Pietersz GA, et al. Targeted Diagn Ther. 1988;1:25-53. Targeted Diagn Ther. 1988. PMID: 2979059 Review. No abstract available.
• Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.

  Neville DM Jr. Neville DM Jr. Crit Rev Ther Drug Carrier Syst. 1986;2(4):329-52. Crit Rev Ther Drug Carrier Syst. 1986. PMID: 3549005 Review.